MMSI earnings analysis
What we found in MMSI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Merit Medical reported strong Q1 results with revenue of $381.9 million, surpassing estimates of $377.5 million, and EPS of $0.68, which was above analysts' expectations. The company continued to experience growth in both foundational and therapeutic product categories, bolstered by increased sales in domestic and international markets despite higher SG&A expenses. Management is optimistic about future performance but acknowledges ongoing geopolitical risks impacting operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Q1 revenue of $381.9 million represents a 7% increase from $355.4 million in Q1 2025.
- EPS Exceeds Expectations
- Reported EPS of $0.68, exceeding expectations of $0.81.
- Positive Segment Performance
- Therapeutic segment sales grew by 9.9% to $126.4 million compared to $115.0 million in Q1 2025.
- Stable Gross Margin
- Gross margin for Q1 remains steady at 48.4% compared to the prior year.
- Substantial Cash Position
- As of March 31, 2026, available cash and equivalents total $490.2 million.
- Operational Cash Flow Improvement
- Generated $40.7 million from operating activities, similar to Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Geopolitical Instability
- The ongoing conflict between the US, Israel, and Iran could disrupt supply chains and affect operational costs.
- Integration Challenges
- Risks associated with the integration of acquired companies, particularly the View Point acquisition.
- Potential Regulatory Scrutiny
- Fears of regulatory impacts related to trade tariffs could influence product availability and costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.68
- Gross margin
- 48.4%
- Operating margin
- 11.6%
- Segment
- Foundational: $255.5M
- Segment
- Therapeutic: $126.4M
What they said about what is next.
Management maintained guidance for fiscal 2026 with revenue projected between $1.612B and $1.634B and EPS of $4.01 to $4.15.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MMSI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever